Advertisement

Understanding the Mechanisms of Cure in Acute Myeloblastic Leukaemia: Towards a Modern Immunotherapy

  • H. G. Prentice
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

The published literature suggests that less than 25% of patients with de novo acute myeloblastic leukaemia (AML), treated by intensive chemotherapy, are cured by this approach [1, 2]. Modest improvements have been claimed for treatment on high-dose cytosine arabinoside (HD-Ara-C) containing combinations [3] and in younger patients on the VAPA protocol [4]. As a rule more than 60% experience disease recurrence [5, 2].

Keywords

Minimal Residual Disease Conditioning Regimen Cytosine Arabinoside Acute Myeloblastic Leukaemia Royal Free Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rees JKH, Gray RG et al. (1986) Lancet ii: 1236–1241CrossRefGoogle Scholar
  2. 2.
    Preisler HD, Anderson K, Cuttner J et al. (1987) Br J Haematol 71: 189–194CrossRefGoogle Scholar
  3. 3.
    Wolff SN, Herzig AW, Phillips GL et al. (1987) Semin Oncol 14: 12–17PubMedGoogle Scholar
  4. 4.
    Weinstein JH, Mayer RJ, Rosenthal DS et al. (1983) Blood 62: 315–319PubMedGoogle Scholar
  5. 5.
    Garson OM, Hagemcijer A, Sakurai M et al. (1989) Cancer Genet Cytogenet 40: 187–202PubMedCrossRefGoogle Scholar
  6. 6.
    International Bone Marrow Transplant Registry (1989) Lancet i: 1119–1122Google Scholar
  7. 7.
    Gratwohl A, Hermans J, Barrett AJ et al. (1988) Lancet i: 1379–1382Google Scholar
  8. 8.
    Pollard, CM, Powles RL, Miller JL (1986) Lancet ii: 1343–1344CrossRefGoogle Scholar
  9. 9.
    Atkinson K, Biggs J, Dodds A et al. (1988) Aust NZ J Med 18: 587–593CrossRefGoogle Scholar
  10. 10.
    Maraninchi D, Gluckman E, Blaise D (1986) Lancet ii: 175–178Google Scholar
  11. 11.
    Weiden PL, Fluornoy N, Thomas ED et al. (1979) N Engl J Med 300: 1068–1073PubMedCrossRefGoogle Scholar
  12. 12.
    Clift RA, Buckner CD, Appelbaum FR et al. (1990) Blood 76: 1867–1871PubMedGoogle Scholar
  13. 13.
    Clift RA, Buckner CD, Appelbaum FR et al. (1990) Blood 76: 1867–1871PubMedGoogle Scholar
  14. 14.
    Burnett AK, Hann IM, Robertson AG et al. (1988) Leukaemia 2: 300–303Google Scholar
  15. 15.
    Ash RC, Jasper D, Lawton CG et al. (1989) Blood 74(1): 163 (abstr)Google Scholar
  16. 16.
    Schattenberg A, De Witte T, Bar B et al. (1989) Bone Marrow Tansplant 4 [Suppl 1]: 111Google Scholar
  17. 17.
    Reittie JE, Gottlieb DJ, Heslop HE et al. (1989) Blood 73: 1351–1358PubMedGoogle Scholar
  18. 18.
    Hercend T, Reinherz ELK, Meuer SC et al. (1983) Nature 301: 158–160PubMedCrossRefGoogle Scholar
  19. 19.
    Price G, Brenner MK, Prentice HG et al. (1989) Br J Cancer 71: 189–194Google Scholar
  20. 20.
    Heslop HE, Gottlieb DJ, Reittie JE et al. (1989) Br J Haematol 72: 122–126PubMedCrossRefGoogle Scholar
  21. 21.
    Kiyohara T, Taniguchi K, Kubota S et al. (1988) J Exp Med 168: 2355–2360PubMedCrossRefGoogle Scholar
  22. 22.
    Leger O, Drexler HG, Reittie JE, et al. (1987) Br J Haematol 67: 273–279PubMedCrossRefGoogle Scholar
  23. 23.
    Gottlieb DJ, Brenner MK, Heslop HE et al. (1989) Br J Cancer 60: 610–615PubMedCrossRefGoogle Scholar
  24. 24.
    Gottlieb DJ, Prentice HG, Heslop HE et al. (1988) Blood 74: 2335–2342Google Scholar
  25. 25.
    Foa R, Fierro MT, Tosti S et al. (1990) Leuk Lymph 1: 113–117CrossRefGoogle Scholar
  26. 26.
    MacDonald D, Jiang YZ, Swirsky D et al. (1991) Br J Haematol 77: 43–49PubMedCrossRefGoogle Scholar
  27. 27.
    Carron JA, Cawley JC (1989) Br J Haematol 73: 168PubMedCrossRefGoogle Scholar
  28. 28.
    Foa R, Caretto P, Fierro NT (1990) Br J Haematol 75: 34–40PubMedCrossRefGoogle Scholar
  29. 29.
    Geller RB, Saral R, Karp JE et al. (1990) Leukemia 4: 313–315PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. G. Prentice
    • 1
  1. 1.Bone Marrow Transplant ProgrammeRoyal Free Hospital School of MedicineLondonUK

Personalised recommendations